2 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Muscle Weakness: new trials by email Literature Review of Muscle Weakness trials Research Report on Muscle Weakness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy AAV9-Follistatin gene therapy, VEGF Plasmid - Age-related Muscle Decline | Phase 1 / Phase 2 | Recruiting | Unlimited Biotechnology LLC | 12 | 2026-06-01 | 2026-07-13 |
| Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases anito-cel, Cyclophosphamide, Fludarabine - Muscular Diseases, Neuromuscular Manifestations | Phase 1 | Recruiting | Kite, A Gilead Company | 30 | 2025-04-30 | 2026-10-22 |
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Frailty (1) · Muscular Atrophy (1) · Muscular Diseases (1) · Myasthenia Gravis (1) · Neuromuscular Manifestations (1) · Sarcopenia (1)
Musculoskeletal Diseases (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Atrophy (1) · Immune System Diseases (1) · Muscular Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Nervous System Neoplasms (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Neuromuscular Junction Diseases (1)
Cyclophosphamide (1) · fludarabine (1)
Kite, A Gilead Company (1) · Unlimited Biotechnology LLC (1)
Honduras (1) · United States (1)